Mackenzie Financial
ANAC

Mackenzie Financial’s ANACOR PHARMACEUTICALS INC COM ANAC Stock Holding History

Mackenzie Financial’s Portfolio ANAC Stock Details ANAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-3,223
Closed -$250K – 889
2015
Q2 		$250K Buy
+3,223
New +$211K ﹤0.01% 784

Other funds holding ANAC

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
RCP
Rho Capital Partners New York $20.4M AUM

Mackenzie Financial's ANAC Position: Q3 2015 in Review

Mackenzie Financial sold out of ANACOR PHARMACEUTICALS INC COM (ANAC) in Q3 2015, closing a stake of 3,223 shares — an estimated $250K sold.

Mackenzie Financial first reported a position in ANAC in Q2 2015 and held it in 1 quarter. The position peaked at $250K in Q2 2015. 213 funds tracked by Wall St. Rank hold ANAC as of Q3 2015.

  • Mackenzie Financial reported no remaining ANACOR PHARMACEUTICALS INC COM position as of Q3 2015 after selling out during the quarter.
  • Mackenzie Financial sold 3,223 ANACOR PHARMACEUTICALS INC COM shares in Q3 2015, an estimated $250K.
  • Mackenzie Financial first reported a position in ANACOR PHARMACEUTICALS INC COM in Q2 2015 and held it in 1 quarter.
  • Mackenzie Financial's ANACOR PHARMACEUTICALS INC COM position peaked at $250K in Q2 2015.
  • 213 funds tracked by Wall St. Rank held ANACOR PHARMACEUTICALS INC COM as of Q3 2015.

Based on Mackenzie Financial's 13F filing for Q3 2015, filed 13 Nov 2015.